Compare Recursion Pharmaceuticals Inc (RXRX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Xylem, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while Xylem, Inc. trades at $101.81 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 11.1× Recursion Pharmaceuticals Inc's market cap, and Xylem, Inc. pays a 1.69% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Xylem, Inc. for 50 Days on average.
| RXRX | XYL | |
|---|---|---|
Market Cap | $2.14B | $23.81B |
Volume | 30,789,535 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $6.79 | $152.95 |
52-Week Low | $2.84 | $100.92 |
Typical Hold Time | 22 Days | 50 Days |
Enterprise Value | $1.66B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
XYL trades at $101.83, down 2.63% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent revenue growth from $5.5B in 2022 to $9.0B in 2025 and net income margin expanding to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump strengthen its industrial water solutions portfolio. XYL has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected on October 27, 2026.
Analyst consensus is mixed with 47.5% buy ratings and a $149.13 price target suggesting 46% upside. Key risks include China market weakness and increased debt from recent acquisitions. The stock offers value with reasonable P/E of 24.28 and strong cash flow generation, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
